印度首次结合血液和数字认知筛查进行非侵入性阿尔茨海默氏测试。 India launches Dendrite Dx, its first non-invasive Alzheimer’s test combining blood and digital cognitive screening.

Dangs Lab博士已推出Dendrite Dx(Dendrite Dx), 这是印度第一个用于早期发现老年痴呆症的非侵入性综合平台, Dr. Dangs Lab has launched Dendrite Dx, India’s first integrated, non-invasive platform for early Alzheimer’s detection, unveiled on World Alzheimer’s Day. 它将数字认知测试与用于pTau-217、Amyloid Beta1-42和ApoE基因定型的血液生物标志分析结合起来,然后是预测性AD2 LC-MS测试,以评估与氨基类有关的大脑变化。 It combines a digital cognitive test with blood biomarker analysis for pTau-217, Amyloid Beta 1-42, and ApoE genotyping, followed by the PrecivityAD2 LC-MS test to assess amyloid-related brain changes. 该系统为PET扫描和脊柱水龙头等昂贵的侵入性方法提供了可扩展、可负担得起的替代方法,同时也为诸如维生素缺乏症和甲状腺问题等可治疗的记忆问题原因进行筛查。 The system offers a scalable, affordable alternative to costly, invasive methods like PET scans and spinal taps, while also screening for treatable causes of memory issues such as vitamin deficiencies and thyroid problems. 它与C2N诊断师合作开发,标志着印度首次获得这一全球公认的测试,从而能够进行早期诊断、更好的治疗规划,并有可能获得新兴疗法。 Developed in partnership with C2N Diagnostics, it marks India’s first access to this globally recognized test, enabling earlier diagnosis, better treatment planning, and potential access to emerging therapies.